The liver is the commonest site of metastatic disease for patients with colorectal cancer, with
at least 25% developing colorectal liver metastases (CRLM) during the course of their …

(1) Background: Colorectal cancer (CRC) is the third most common cancer and the second
leading cause of cancer-related mortality worldwide. Up to 50% of patients with CRC …

Background Hepatic resection is considered the optimal potentially curative treatment for
colorectal liver metastases (CRLM). Following resection, up to two-thirds of patients will …

PURPOSE To assess the effects of bevacizumab plus modified fluorouracil, leucovorin, and
oxaliplatin (mFOLFOX6) as first-line treatment of RAS mutant unresectable colorectal liver …

Objective: The aim of this study was to describe laparoscopic anatomical parenchymal
sparing liver resections for hepatocellular carcinoma (HCC) and colorectal liver metastases …

Aims To assess the safety and efficacy of parenchymal‐sparing hepatectomy (PSH) as a
treatment of colorectal liver metastases (CLM). Methods A comprehensive medical literature …

Simple Summary Colorectal cancer (CRC) is a leading cause of death among cancer
patients, and the liver is the most common visceral metastatic site. Despite promising …

There is a critical need for development of improved methods capable of accurately
predicting the RAS (KRAS and NRAS) and BRAF gene mutation status in patients with …

Public initiatives to reduce the exposure to known risk factors, including smoking, and the
uptake of colorectal cancer (CRC) screening programs have led to a steady decline in CRC …

Metastatic colorectal cancer (mCRC) patients have poor chances of long term survival,
being< 15% of them still alive after 5 years from diagnosis. Nonetheless, patients with …